Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 9 recruiting now full pipeline

Dry Eye: full-pipeline trial registry

9 of 42 indexed Dry Eye trials are currently recruiting.

Corpus placement: #347 of 28,707 conditions by registered trial count.

42 US clinical trials · 9 currently recruiting · #347 of 28,707 conditions by registered trial count

Dry Eye: 42 US clinical trials tracked, 9 recruiting.

Dry Eye is the subject of 42 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 16 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is Toyos Clinic, running 3 of these trials.

Enrollment posture brief

Registry condition dry-eye

OPEN 9 | RECR 21% | LATE 16 | EARLY 11 | RANK #347 | SPON 3

Nearest open-share peer: Cervical Adenocarcinoma (21% recruiting · 14 trials)

Gestational Diabetes64.3%Essential Tremor57.1%Epithelial Ovarian Cancer42.9%Graft-Versus-Host Disease28.6%Dry Eye (this)21%
Open-enrollment share among volume-matched conditions near Dry Eye

Dry Eye lists 9 open slots (21% of 42 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Dry Eye on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Dry Eye is recruiting below its size-band peers.

    9 of 42 indexed trials (21.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Dry Eye trials is spread across many organizations.

    Toyos Clinic accounts for 3 of 42 trials (7.1%). 29 distinct sponsors appear on at least one study for this condition label.

  3. Most Dry Eye trials plan to enrol fewer than 100 people.

    Median target enrolment is 50 among the 42 trials that report a genuine target (sentinel values excluded). 29 of those (69%) plan for fewer than 100 participants.

  4. Dry Eye research is mostly interventional.

    39 interventional and 3 observational studies make up this index (92.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 28Phase 33Phase 413

Open and recent trials

42 total, page 1 of 1

RECRUITING Phase 2 160 participants

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

Vanda Pharmaceuticals

NCT07179055

RECRUITING Phase 4 60 participants

Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK

Vance Thompson Vision

NCT07155070

RECRUITING NA 60 participants

The THINK Study Incidence of Neurotrophic Keratopathy)

Research Insight

NCT06482164

RECRUITING NA 40 participants

Low Level Light Therapy & Skin Pigmentation

University of Houston

NCT07173530

RECRUITING Phase 2 40 participants

A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

Vanda Pharmaceuticals

NCT06296966

RECRUITING Phase 4 40 participants

Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work

Southern College of Optometry

NCT07266948

RECRUITING Phase 4 36 participants

Quality of Life in Presbyopic Patients Who Are Treated With Qlosi

Southern College of Optometry

NCT07113210

RECRUITING Phase 4 35 participants

Performance of Systane PRO Versus Refresh Optive Mega-3

Scripps Poway Eyecare and Optometry

NCT06975891

RECRUITING Phase 4 20 participants

Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease

Toyos Clinic

NCT06964269

ACTIVE NOT RECRUITING Phase 4 216 participants

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

Bausch & Lomb Incorporated

NCT06565650

ACTIVE NOT RECRUITING Phase 2 30 participants

Phase 2b Controlled Study of Dosing Techniques - Part B

IVIEW Therapeutics

NCT07161011

ACTIVE NOT RECRUITING Phase 4 10 participants

DOMPE -MT Neurotrophic Keratitis

Toyos Clinic

NCT06947850

COMPLETED Phase 2 718 participants

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

Novartis Pharmaceuticals

NCT04391894

COMPLETED Phase 3 422 participants

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Aldeyra Therapeutics

NCT03879863

COMPLETED Phase 3 361 participants

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Aldeyra Therapeutics

NCT05062330

COMPLETED Phase 2 160 participants

A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period

Alacrity Biosciences

NCT00439400

COMPLETED Phase 2 150 participants

An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye

Dompé Farmaceutici S.p.A

NCT03019627

COMPLETED Phase 1 132 participants

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Santen

NCT01118754

COMPLETED NA 109 participants

Evaluation of SYSTANE Ultra Lubricant Eye Drops

Alcon Research

NCT00702377

COMPLETED Phase 4 104 participants

A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear

Bausch & Lomb Incorporated

NCT07054606

COMPLETED Phase 3 104 participants

Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)

Dompé Farmaceutici S.p.A

NCT05133180

COMPLETED 103 participants

Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia

Nvision Laser Eye Centers

NCT05895500

COMPLETED Phase 4 100 participants

The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study

Research Insight

NCT04669561

COMPLETED Phase 2 70 participants

Treatment of Patients With Blepharitis and Facial Rosacea

Galderma R&D

NCT00560703

COMPLETED Phase 1 64 participants

Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

Cambium Bio Limited

NCT03414645

COMPLETED 60 participants

Tear Dynamics After Restasis Treatment in Dry Eye Patients

University of Miami

NCT00706940

COMPLETED NA 60 participants

Dailies Total 1 Sphere Contact Lenses

University of Alabama at Birmingham

NCT05239494

COMPLETED Phase 4 52 participants

Oasys vs. Extreme H20 Xtra 59

Innovative Medical

NCT00477763

COMPLETED NA 50 participants

Evaluation of Extended Tear Film Break Up Time (TFBUT) With an Ocular Emulsion

Alcon Research

NCT01368198

COMPLETED Phase 4 46 participants

Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort

University of Alabama at Birmingham

NCT03682809

COMPLETED Phase 2 43 participants

Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?

University of Miami

NCT02701764

COMPLETED Early Phase 1 36 participants

Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus

Illinois College of Optometry

NCT04418999

COMPLETED 32 participants

Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal Sensation and Dry Eye

Allergan

NCT01161771

COMPLETED Phase 4 30 participants

Digital Device Users Who Are Treated With Systane Hydration PF

University of Alabama at Birmingham

NCT04837807

COMPLETED Phase 4 30 participants

Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms

Lifelong Vision Foundation

NCT03451396

COMPLETED NA 29 participants

Study of the TearCare System in Dry Eye Disease

Sight Sciences

NCT03588624

COMPLETED NA 20 participants

Acute Comfort of Lubricant Eye Drops FID 112903

Alcon Research

NCT00673855

COMPLETED NA 20 participants

Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea

Mayo Clinic

NCT03194698

COMPLETED NA 20 participants

Tear Lipid Layer Thickness Assessments With Perfluorohexyloctane Eye Drops

Ohio State University

NCT05288582

COMPLETED NA 19 participants

Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease

Toyos Clinic

NCT03658811

COMPLETED NA 17 participants

Corneal Epithelial Stem Cells and Dry Eye Disease

Sloan W. Rush, MD

NCT03302273

COMPLETED NA 17 participants

A Study to Evaluate the Safety and Effectiveness Assessments of Restylane-Defyne for Punctual Occlusion

John C Meyer, MD

NCT04022382

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 8
Phase 3 3
Phase 4 13

Named interventions

Most-linked intervention names on Dry Eye records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
VSJ-110 Drug
2 trials
Vehicle Other
2 trials
placebo Drug
2 trials
Restylane Defyne Device
1 trials
Optive Other
1 trials
SYSTANE Ultra Other
1 trials
TearCare Device
1 trials

US sites by state

Facility locations filed on Dry Eye trials. A trial with sites in several states counts in each.

California 14 trials
Tennessee 10 trials
Florida 7 trials
Texas 6 trials
Massachusetts 6 trials
Ohio 5 trials
Pennsylvania 4 trials
New York 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Dry Eye page

42 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dry Eye condition card totals 42 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.